| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Zanidatamab-hrii | 2026-02-01 |
| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Zanubrutinib | 2026-02-01 |
| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Ziftomenib | 2026-02-01 |
| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Zoledronic Acid | 2026-02-01 |
| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Cerumen Removal (CC.PP.008) | 2026-02-01 |
| UHC UMR Medical and Drug | Infliximab (Avsola®, Inflectra®, Remicade®, & Renflexis®) – Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC UMR Medical and Drug | Intravenous Iron Replacement Therapy (Feraheme®, Injectafer®, & Monoferric®) – Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Surest Medical and Drug | Infliximab (Avsola®, Inflectra®, Remicade®, & Renflexis®) – Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Surest Medical and Drug | Intravenous Iron Replacement Therapy (Feraheme®, Injectafer®, & Monoferric®) – Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Ablative Treatment for Spinal Pain – Commercial and Individual Exchange Medical Policy | 2026-02-01 |